Tagged with GE

China China has made major healthcare strides over the past decade with regulatory reforms, infrastructure improvements, and the advancement of universal healthcare. While the COVID-19 pandemic revealed the need for further reform, the country continues to pursue the healthcare transformation goals established in its Health China 2030 program. These aspirations are…

Rare Diseases With February’s Rare Disease Day behind us, it can be easy to forget the impact of these diseases on individuals, their families and care givers, and our communities throughout the other 11 months of the year. But if we – in healthcare, in government and in academia – are to…

Argentina Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful strategy predicated on customising its offering to each country and balancing local management autonomy with a strong company culture.  …

China John Oyler, co-founded the Beijing-based biotech BeiGene in 2010 with the idea of building a global biopharmaceutical company in China and running clinical trials of an international standard there. With his entrepreneurial background and knowledge of China and its life sciences ecosystem, Oyler has led the company through its consolidation…

Colombia Tecnoquímicas recently invested over USD 250 million in its Colombian manufacturing plants, signifying the company’s continuing faith in its home market. Executive Vice-President Emilio Sardi Aparicio outlines the regulatory and access landscape in Colombia today, how the firm’s international footprint within Latin America has evolved, and its approach to the…

Greece Spyridon Gkikas outlines how GE HealthCare’s global transformation is playing out in Greece as well as the opportunities and challenges of bringing cutting-edge medical technology into the Greek healthcare system.   EU Recovery and Resilience Funding (RRF) is coming online, creating an opportunity for Greece to improve its healthcare system,…

Germany While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team in place. Former Roche Pharma head Bill Anderson is yet to lay out his strategic priorities as CEO of Bayer…

Greece Evangelos Zekkas outlines Help Pharma’s internationalisation journey in recent years, with the Greek firm’s exports now accounting for 60 percent of production and 50 percent of turnover. Zekkas, the company’s long-serving president and managing director, also gives his thoughts on Greek pharma’s role in Europe post-COVID more broadly, the challenges…

Argentina Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful strategy predicated on customising its offering to each country and balancing local management autonomy with a strong company culture, as…

USA In the current economic environment companies are faced with increased pressure to manage cash and meet investor expectations with tightened budgets. Life science industry CFOs, as a recent survey and webinar reveal, are looking to preserve and generate cash by making their companies more efficient and building partnerships while confronting…

China A roundup of some of the biggest pharma and biotech news from China including the collaboration between Elektr and Sinopharm; Biocytogen’s partnership with Janssen and deal with Chipscreen Biosciences; China’s first personalised neoantigen-targeted cancer vaccine approval; the final green light for Sino Biopharm’s purchase of F-star, and AstraZeneca’s deal with…

Global In the largest pharma acquisition in four years, Pfizer has picked up oncology biotech Seagen for USD 43 billion. The deal, which could signal a rebound in M&A activity as big pharma companies look to renew their pipelines in preparation for post-COVID and off-patent losses, bolsters Pfizer’s continuing push into…